[ad_1]
(AOF) – Genfit (+5.80% to 4.56 euros) today announced the conditional approval by the European Commission of Iqirvo (elafibranor) 80mg tablets for the treatment of Primary Biliary Cholangitis (PBC). This biotech company committed to improving the lives of patients with rare, life-threatening liver diseases states that this decision follows the positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) on July 26, 2024, and the accelerated approval by the US FDA on June 10, 2024.
“The approval of Iqirvo in the EU is another milestone for Genfit,” said CEO Pascal Prigent. “It provides further validation of our scientific and clinical capabilities, demonstrating that we are able to take a drug candidate from discovery to the end of a Phase 3 trial, making Iqirvo a new treatment option for patients.”
He added that “the expected payment of €26.5 million, upon approval of pricing and reimbursement of Iqirvo in three European countries, will allow us to continue developing our robust pipeline in other serious liver diseases with unmet medical need, including Acute On-Chronic Liver Failure.”
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from sources it considers the most reliable. However, the reader remains solely responsible for their interpretation and the use of the information made available to him. Thus, the reader must hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article? Share it with your friends using the buttons below.
[ad_2]
Source link -85